Back to Conditions

Etanercept: A Different Kind of TNF Blocker

Etanercept: A Different Kind of TNF Blocker
Prescription Medicines Editorial 15 August 2025

Etanercept blocks tumour necrosis factor, like adalimumab, but it is built differently. Adalimumab is a monoclonal antibody that binds TNF wherever it is, including on cell surfaces. Etanercept is a fusion protein - two copies of the TNF receptor joined to an antibody fragment - which acts as a decoy, soaking up circulating TNF. That structural difference is not academic: it changes the infection profile, and it decides what etanercept cannot treat.

Follow the plan your specialist gave you. This guide contains no doses.

It does not work in Crohn's disease

This is the clearest consequence of the structural difference. Adalimumab and infliximab are effective in Crohn's disease; etanercept is not, and trials showed no benefit.

The explanation is thought to lie in what antibodies do beyond neutralising TNF - binding membrane-bound TNF on immune cells and triggering their destruction, which etanercept does not do.

So if you have inflammatory bowel disease alongside arthritis, etanercept is not the right biologic, and the choice will be made with that in mind.

See adalimumab.

What it does treat

Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis, plaque psoriasis, and juvenile idiopathic arthritis.

In rheumatoid arthritis it is often given alongside methotrexate, which improves its effectiveness and reduces the formation of antibodies against it.

That means the methotrexate rules apply too - weekly dosing, folic acid on different days, and blood monitoring. See methotrexate.

Tuberculosis

Etanercept carries a lower risk of reactivating latent tuberculosis than the antibody TNF blockers - again because it does not destroy the immune cells that maintain the granulomas walling off dormant infection.

Lower is not zero. Screening before starting is still required - history, chest X-ray and an interferon gamma release assay - along with hepatitis B and C serology.

Where latent TB is found, treatment for it is given before or alongside.

Report a persistent cough, fever, night sweats or unexplained weight loss at any point, and mention that you take a TNF inhibitor.

Infection generally

Serious bacterial, fungal and viral infections are more common, and the usual signs can be blunted.

Seek medical advice promptly for fever, persistent sore throat, a cough that will not settle, burning on passing urine, or a wound that is not healing.

Treatment is paused during a significant infection and restarted once it has resolved.

Carry your biologic alert card and show it to anyone treating you, particularly in an emergency department.

See infection risk on immune-suppressing medicines.

Vaccines

Live vaccines are avoided during treatment - yellow fever, MMR, live shingles vaccine and the live nasal flu vaccine for children.

Ideally live vaccines are given before starting, with an interval beforehand.

Inactivated vaccines are recommended - annual influenza, pneumococcal, COVID and the non-live shingles vaccine.

Check with your team before any vaccination, including travel vaccines - see travel vaccines.

Injecting it

Etanercept is given by subcutaneous injection, once or twice weekly depending on the regimen, into the thigh, abdomen or upper arm.

Rotate sites and avoid areas that are tender, bruised or affected by psoriasis.

Injection site reactions are common - redness, itching and swelling, more so than with some other biologics. They usually settle over days and become less frequent with time.

Letting it reach room temperature for around half an hour before injecting reduces stinging considerably.

Store in the fridge, never frozen, and use a cool bag for travel - see medicines that need the fridge and flying with prescription medicines.

Used devices go in a sharps bin - see needles and sharps disposal.

Biosimilars

Several biosimilar versions are available and widely used in the NHS. They are highly similar rather than identical, and are approved on evidence of equivalent effect.

What usually changes is the device. If your product changes, ask to be shown the new pen rather than assuming it works the same way.

See why some medicines are prescribed by brand.

If it stops working

Some people develop antibodies against etanercept over time, reducing its effect - though this happens less often than with the antibody TNF blockers.

Loss of effect after a period of good response is worth reporting rather than enduring. The answer is usually switching to a different biologic rather than increasing the dose, and there are several with different mechanisms available.

Other effects

Headache, rash and nausea are common.

Report a new or worsening rash - psoriasis paradoxically induced by TNF inhibitors is recognised, as is a lupus-like reaction.

Report numbness, tingling or visual disturbance, since demyelinating conditions are a rare association, and new breathlessness or ankle swelling, since heart failure can worsen.

Blood counts and liver function are monitored - see monitoring long-term medicines.

Non-melanoma skin cancer appears somewhat more common with TNF inhibitors, so sun protection matters and any new or changing skin lesion should be reported.

See also Methocarbamol: A Muscle Relaxant for Short Use, and the Conditions section for more on what medicines are prescribed for.